(Q34722948)

4 August 2017

1 reference

title

Amyloidosis: prognosis and treatment (English)

1 reference

4 August 2017

Gertz MA

1

1 reference

4 August 2017

Kyle RA

series ordinal

2

1 reference

4 August 2017

language of work or name

1 reference

1 October 1994

1 reference

Seminars in Arthritis and Rheumatism

4 August 2017

published in

1 reference

4 August 2017

volume

24

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

124-138

1 reference

Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Jaw claudication in primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Hyposplenism in primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

The natural history of peripheral neuropathy in primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Doppler characterization of left ventricular diastolic function in cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

The course of renal amyloidosis with uraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Beta 2-microglobulin predicts survival in primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Resolution of renal amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Colchicine therapy of the renal amyloidosis of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Remission of nephrotic syndrome related to AA amyloidosis after hepatic adenomectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Renal amyloidosis in juvenile chronic arthritis: evolution after chlorambucil treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Laser photoradiation therapy for tracheobronchial amyloid

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Experience with dimethyl sulfoxide treatment for primary localized amyloidosis of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Primary localized amyloidosis of the bladder: a case of AL (lambda) amyloid protein and combination therapy using dimethyl sulfoxide and cepharanthin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Colchicine therapy in primary amyloidosis of the bladder: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Selective binding of nifedipine to amyloid fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Continuous ambulatory peritoneal dialysis in systemic amyloidosis and end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Replacement therapy in end-stage renal amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Outcome of patients with secondary amyloidosis in dialysis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Recurrence of renal amyloid and de novo membranous glomerulonephritis after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Systemic amyloidosis involving two renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Renal transplantation in 45 patients with amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Treatment of experimental murine amyloidosis with dimethyl sulfoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

DMSO and colchicine therapy in amyloid disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Dimethyl sulfoxide in the treatment of AA amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Amyloidosis in children with familial Mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Familial Mediterranean fever. A survey of 470 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Colchicine therapy for familial mediterranean fever. A double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

A controlled trial of colchicine in preventing attacks of familial mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Long-term colchicine treatment in children with familial mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Reversal of the Nephrotic Syndrome by Colchicine in Amyloidosis of Familial Mediterranean Fever

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Colchicine in the treatment of AA and AL amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Prolonged colchicine treatment in four patients with amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Letter: Improvement in amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

[Primary amyloidosis with nephrotic syndrome: 5 year follow-up under polychemotherapy. A case report (author's transl)]

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Objective response in amyloidosis treated with intermittent chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

The Successful Treatment of Primary Amyloidosis with Intermittent Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Therapy of Primary Amyloidosis With Melphalan and Prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Successful treatment of hemorrhagic syndrome due to an acquired, combined deficiency of factors VII and X in a patient with multiple myeloma and amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Amyloid myopathy and myeloma: response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Unusual longevity in primary systemic amyloidosis: a 19-year survivor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

AL amyloidosis: therapeutic response in two patients with renal involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Primary amyloidosis associated with multiple myeloma. Predictors of successful therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Treatment of AL amyloidosis with melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Free Radical Theory of Aging: Inhibition of Amyloidosis in Mice by Antioxidants; Possible Mechanism*

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Phase II trial of alpha-tocopherol (vitamin E) in the treatment of primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Amyloidosis (AA type) with gastrointestinal involvement: resolution of gastric amyloid deposition in parallel with disappearance of the serum component of amyloid A protein

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Transplantation for renal amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Response of systemic amyloidosis to dimethyl sulfoxide.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Improvement of endoscopic and histologic findings of AA-type gastrointestinal amyloidosis by treatment with dimethyl sulfoxide and prednisolone.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Successful Treatment of Primary Amyloidosis with Dimethylsulfoxide and Cytoreductive Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

Amyloidosis of immunoglobulin origin: useful treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980006-X

7 January 2021

10.1016/S0049-0172(05)80006-X

Identifiers

DOI

1 reference

4 August 2017

1 reference